Evolent Health Q2 Revenue Jumps 47% on New Performance Suite Contracts, Raises Full-Year Outlook
EVH sits 86% above its 52-week low of $2.095.
Summary
Evolent Health reported Q2 2026 revenue of $652.5 million, a 47% increase year-over-year, driven by new Performance Suite contracts. The company raised full-year guidance and issued a bullish 2027 outlook, but also disclosed that its CEO and President adopted 10b5-1 trading plans to sell shares.
Key Events · Earnings and Guidance · EVH
-
Revenue Surges 47%
Q2 2026 revenue reached $652.5 million, up from $444.3 million a year ago, driven by new Performance Suite contract go-lives and expanded oncology services.
-
Full-Year Guidance Raised
Management raised its full-year 2026 outlook and issued a bullish 2027 outlook, reflecting confidence in the growth trajectory of its specialty care platform.
-
Medical Expense Ratio Spikes
The Medical Expense Ratio (MER) increased to 95.3% from 80.0% as new Performance Suite contracts ramp up, indicating near-term margin pressure.
-
CEO and President Adopt 10b5-1 Plans
CEO Seth Blackley adopted a plan to sell up to 298,129 shares starting December 15, 2026; President Daniel McCarthy adopted a plan for up to 201,320 shares starting August 21, 2026.
Analysis · EVH · Trade & Services
Evolent Health delivered a strong Q2 with revenue up 47% to $652.5 million, driven by new Performance Suite contract go-lives. The company raised its full-year guidance and issued a bullish 2027 outlook, signaling confidence in its specialty care management platform. However, the Medical Expense Ratio spiked to 95.3% from 80.0% as these new contracts ramp up, and cash reserves declined to $115.7 million. Separately, the CEO and President adopted 10b5-1 trading plans to sell up to 298,129 and 201,320 shares respectively, which could create overhang. The combination of strong top-line growth, improved guidance, and insider selling plans makes this a notable update for investors.
At the time of this filing, EVH was trading at $3.89 on NYSE in the Trade & Services sector, with a market capitalization of approximately $346.4M. The 52-week trading range was $2.10 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.